Moreover, using CD123 chimeric antigen receptor (CAR) T-cells would permit to target pDC and blasts in pDC-AML more efficiently, as reported in new preclinical and clinical approaches in BPDCN [137] and AML [138]. Here, IL3RA is linked to acute myeloid leukemia.